Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | FABP4 | P15090 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | MMP1 | P03956 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP9 | P14780 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | FGB | P02675 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562243 | 0.90 | L3MBTL1 (0.67) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL8576092 | 0.89 | MAPT (0.69) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL4746858 | 0.87 | FABP4 (0.68) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL5963342 | 0.86 | FABP4 (0.76) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL4747454 | 0.86 | FABP4 (0.66) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL3867855 | 0.84 | CA1 (0.59) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL11448202 | 0.83 | L3MBTL1 (0.59) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL17101162 | 0.83 | L3MBTL1 (0.59) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL17703608 | 0.80 | FABP4 (0.63) | L3MBTL1FABP4KMT2AMEN1MAPT | |
| SCHEMBL6019928 | 0.79 | L3MBTL1 (0.55) | L3MBTL1FABP4KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10448632-B2 | Control of plant stress tolerance, water use efficiency and gene expression using novel ABA receptor synthetic agonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-22 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655641-B2 | Sulfonamide derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1597248-B1 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | LILLY CO ELI (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | US | disclosed |
| EP-1597248-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004073606-A2 | SULFONAMIDE DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2002-04-18 | — | — | US | disclosed |
| US-6235794-B1 | ANTICANCER AGENT | UNIVERSITY OF FLORIDA | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | SRM, SLC7A1, CATSPER1 | L3MBTL1 3921/4885FABP4 3667/4885KMT2A 2238/4885 |
| US-10448632-B2 | Control of plant stress tolerance, water use efficiency and gene expression using novel ABA receptor synthetic agonists | NPBWR1, AVPR1A, AAK1 | L3MBTL1 1253/4885FABP4 3744/4885KMT2A 2431/4885 |
| US-20060217433-A1 | Sulfonamide derivatives as ppar modulators | PPARD, PPARA, PPARG | L3MBTL1 4653/4885FABP4 5/4885KMT2A 2003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.